Troy Wilson, Kura Oncology CEO
February 24, 2023 11:01 AM ESTUpdated 02:58 PM
R&D

Ku­ra On­col­o­gy drops mul­ti­ple clin­i­cal pro­grams for J&J-dis­cov­ered tip­i­farnib

Paul Schloesser

Associate Editor

Ku­ra On­col­o­gy is ax­ing all but one clin­i­cal de­vel­op­ment pro­gram in­volv­ing an old Janssen can­di­date.

Ac­cord­ing to an SEC fil­ing on …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

You bet your life: Af­ter I was di­ag­nosed with a rare can­cer, I dis­cov­ered how a small band of physi­cian-sci­en­tists ...

Nu­ra Bio rais­es $68M for clin­i­cal tests of SARM1 in­hibitor to po­ten­tial­ly slow or pre­vent nerve de­gen­er­a­tion

Why did Eli Lil­ly ask a pa­tient on a com­pound­ed GLP-1 drug for their med­ical in­for­ma­tion?

Roche out­lines com­mer­cial man­u­fac­tur­ing strat­e­gy for GLP-1/GIP as­sets 

A VC-backed ge­net­ic test­ing start­up to 'con­sid­er' mak­ing an of­fer to buy 23andMe

sponsored

Break­ing down si­los with a new quan­ti­ta­tive ap­proach to drug de­vel­op­ment

A service from the Financial Times